Alopecia Areata: Causes, Treatments, and What to Expect

Alopecia areata is autoimmune disease, not a cosmetic problem. The framing matters because it shapes who you should see, what treatments are worth considering, and what to expect. It also matters because much of the public conversation gets it wrong by treating AA as just another type of hair loss.

The condition affects roughly 2% of people at some point in life¹ , often onset in childhood or early adulthood. The course is unpredictable: some people have a single patch that regrows on its own within a year and never recurs; others lose all scalp hair (totalis) or all body hair (universalis) and live with it for years or permanently. The treatment landscape has changed substantially in the last few years with the FDA approval of JAK inhibitors for severe disease.

What’s actually happening

In alopecia areata, the immune system attacks anagen-phase hair follicles. Specifically, T-cells target the hair bulb, disrupting the growth phase and causing the follicle to enter a dystrophic catagen and shed¹ . Importantly, the follicles themselves are not destroyed. They remain alive, which is why regrowth is biologically possible at any point and why the condition is non-scarring.

The trigger for the autoimmune attack isn’t fully known. Genetics matter (first-degree relatives of someone with AA have an elevated risk), and so do environmental factors that haven’t been pinned down. Stress is often blamed, but the evidence that psychological stress causes AA (rather than coexisting with it) is mixed at best.

AA frequently coexists with other autoimmune conditions: Hashimoto’s thyroiditis, vitiligo, type 1 diabetes, and atopic conditions (eczema, asthma). This pattern reflects shared immunologic predisposition rather than one condition causing another.

Subtypes and presentation

The forms of AA differ in extent more than in mechanism:

• Patchy alopecia areata. One or more discrete round/oval bald patches, the most common form.
• Alopecia totalis. Complete loss of all scalp hair.
• Alopecia universalis. Complete loss of all body hair, including eyebrows, eyelashes, body and pubic hair.
• Ophiasis. Band-like loss along the back and sides; tends to be more refractory to treatment.
• Diffuse alopecia areata (alopecia incognita). Diffuse thinning rather than patches; easily missed and misdiagnosed as telogen effluvium.

The classic presentation is sharply-bordered round or oval patches with smooth, unscarred skin and “exclamation mark” hairs at the borders, which are short broken hairs that taper toward the scalp. The patches usually appear over days to weeks, not months. Nail involvement (pitting, ridging, opacification) is common in extensive disease and a poor-prognosis sign.

Course and prognosis

The course is highly variable, which is part of what makes AA emotionally hard to live with. You don’t know whether your single patch is going to regrow in three months and never return, or whether you’re at the start of a longer trajectory.

The general statistics:

• For limited patchy AA, around 50% of patients see spontaneous regrowth within 12 months without any treatment¹ .
• Around 30% develop additional patches or recurrences over time.
• Roughly 5–10% progress to totalis or universalis, often with a poorer outlook for spontaneous regrowth¹ .
• Earlier onset, extensive disease, ophiasis pattern, atopic background, and nail involvement all predict a more refractory course.

A more practical framing: severity at diagnosis isn’t destiny, but it does shift the probability distribution. Limited single-patch AA in an adult with no family history and no nail changes has a substantially better outlook than extensive AA in a child with eczema and pitted nails.

Diagnosis

Most cases are diagnosed clinically. A dermatologist examines the scalp, confirms the sharp borders and smooth scalp, looks for exclamation-mark hairs and nail involvement, and the picture is unambiguous. Trichoscopy (scalp magnification) shows characteristic features (yellow dots, black dots, broken hairs).

In atypical cases (diffuse AA, or AA superimposed on another hair loss type) a punch biopsy under local anaesthetic can confirm. The biopsy shows lymphocytic infiltrate around anagen follicles (“swarm of bees” on histology).

Bloods aren’t required for diagnosis but are often done to screen for associated autoimmune conditions: TSH (and free T4) for thyroid disease, and ANA in some cases. Vitamin D levels are also commonly checked given some evidence of association. We cover the typical panel in our blood tests for hair loss guide.

Treatment, by severity

Limited patchy AA (less than ~50% scalp involvement)

The first-line approaches:

Intralesional corticosteroids. A dermatologist injects triamcinolone acetonide (typically 2.5–10 mg/mL) directly into the bald patches. Done at 4–6 week intervals. The strongest evidence base for limited AA⁴ . Local side effects are mild skin atrophy at injection sites.

Topical corticosteroids. Strong topical steroids (clobetasol propionate 0.05%, or similar) under occlusion. Useful for patients who don’t tolerate injections or for paediatric cases. Less potent than intralesional but more accessible.

Topical minoxidil. Sometimes added as adjunct, particularly during the regrowth phase. Limited standalone evidence in AA, but reasonable in combination.

Topical immunotherapy (DPCP, SADBE). Specialised treatment that deliberately induces a contact dermatitis on the scalp; the resulting inflammation displaces the AA inflammation in some patients. Used for extensive disease, mostly at specialised hair clinics.

For many patients with a single new patch, watchful waiting is also reasonable. Given the ~50% spontaneous regrowth rate over 12 months, treatment isn’t always strictly necessary. The decision often comes down to how visible the patch is, how distressing it is, and whether new patches are appearing.

Severe AA (alopecia totalis, universalis, or extensive patchy AA)

The treatment landscape changed in 2022 with the approval of baricitinib² , followed by ritlecitinib in 2023³ . Three oral JAK inhibitors are now FDA-approved for severe AA:

A few things to know about JAK inhibitors:

• They work by suppressing the immune signalling that drives the AA inflammation. Specifically, they inhibit JAK enzymes that mediate cytokine signalling in T-cells.
• Response takes time. Visible regrowth typically begins by month 3, with maximum effect by month 9–12. Trials run 24–36 weeks for primary endpoints.
• The response rate is meaningful but not universal. Roughly a third of patients with severe AA achieve near-full scalp coverage² . Others see partial regrowth; some don’t respond.
• Stopping reverses the gains. JAK inhibitors are maintenance therapy, not a cure. Discontinuation typically leads to relapse over months.
• Side effects are systemic. Increased risk of infections (including herpes zoster), elevated cholesterol and liver enzymes, and (based on rheumatology data) concerns about cardiovascular events and malignancy at higher doses. Routine monitoring (CBC, lipid panel, LFTs) is required.
• Cost. All three are expensive (often >$3,000–$5,000/month at list price). Insurance coverage varies; manufacturer patient-support programmes exist.

The decision to start a JAK inhibitor is significant. It’s the right choice for many patients with severe disease, but it’s not a casual prescription. This is a conversation for a dermatologist who manages AA regularly, ideally one familiar with all three options.

Other treatments

• Oral corticosteroids (prednisone). Sometimes used short-term to halt rapid progression. Not for long-term use due to side effects. Relapse on stopping is common.
• Methotrexate, azathioprine, cyclosporine. Older immunosuppressants used pre-JAK era. Largely supplanted by JAK inhibitors for severe disease but still used when JAK inhibitors aren’t accessible or appropriate.
• Excimer laser. Small evidence base for limited patchy AA.

What doesn’t work (despite the marketing)

• Most “alopecia areata” supplements sold online. No RCT evidence in AA.
• Diet changes (gluten-free, anti-inflammatory diets). No high-quality evidence that any specific diet alters AA course in the absence of an actual food sensitivity.
• Essential oils, scalp massages, “natural” topicals. No evidence at the level required to recommend over established treatments.
• CBD/cannabis. No controlled evidence in AA.
• Stress-reduction alone. Managing stress is good for general wellbeing and may support quality of life, but it isn’t a treatment for AA in the medical sense.

Living with AA

Several things matter that don’t show up in the medical guidelines:

• Wigs, scalp coverings, microblading for eyebrows, lash extensions. Cosmetic options have improved substantially. Medical-grade wigs are sometimes covered by insurance for AA. Eyebrow microblading and lash strips can restore the most visible features for those with totalis or universalis.
• Sun protection. Hairless scalp burns easily. SPF 50+ on bare scalp, hat, etc.
• Eye protection. Without lashes (and sometimes brows), eyes are more exposed to dust and debris. Wraparound sunglasses help.
• Mental-health support. AA carries higher rates of anxiety and depression than the general population⁵ . The relationship is not just about appearance. It’s the unpredictability and the autoimmune-disease framing of a condition that affects how others see you. Therapy and peer communities (NAAF, the National Alopecia Areata Foundation; Alopecia UK) are concrete supports.

When to see a dermatologist

• Any sharply-bordered patch of hair loss with a smooth scalp inside it
• Rapid progression, multiple new patches, or beard/eyebrow involvement
• Nail changes (pitting, ridging) alongside hair loss
• Recurrent AA episodes, where managing the long-term course needs a clinician
• You’re considering a JAK inhibitor (these need a specialist)
• Anxiety, depression, or other psychological impact significant enough to be affecting your life

A board-certified dermatologist who manages AA regularly is the right specialist. Hair restoration clinics, trichologists, and medspas are not equipped for autoimmune disease management, and the framing of AA as a “cosmetic” issue at such places is a clue that you’re in the wrong place.

What this article doesn’t cover

We’ve focused on adult AA and the medical framework. Paediatric AA has overlapping treatment but different considerations (psychological impact, school environment, and dosing of newer agents in adolescents). We’ve also not covered alopecia areata in the context of pregnancy specifically, or the full landscape of clinical trials currently recruiting, since that landscape changes month to month.

AA is a hard condition to live with not just because of how it looks, but because of how unpredictable it is. If it’s affecting your wellbeing, talking to a GP or dermatologist is a good first step, and so is connecting with a peer community. The isolation around AA is significant and the existing patient organisations exist for good reason. You’re not alone in finding it hard. Anything in this article is general education, not personal medical advice.